Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective

Overview

Journal Sci Rep

Specialty Science

Date 2015 Oct 24

PMID 26492952

Citations 16

Authors

Hala H Mosli

Ahmed Esmat

Reem T Atawia

Sherif M Shoieb

Hisham A Mosli

Ashraf B Abdel-Naim

Affiliations

Soon will be listed here.

Abstract

Benign prostatic hyperplasia (BPH) is uncontrolled proliferation of prostate tissue. Metformin, a widely prescribed anti-diabetic agent, possesses anticancer activity through induction of apoptotic signaling and cell cycle arrest. This study aimed to investigate the protective effect of metformin against experimentally-induced BPH in rats. Treatment with 500 and 1000 mg/kg metformin orally for 14 days significantly inhibited testosterone-mediated increase in the prostate weight &prostate index (prostate weight/body weight [mg/g]) and attenuated the pathological alterations induced by testosterone. Mechanistically, metformin significantly protected against testosterone-induced elevation of estrogen receptor-α (ER-α) and decrease of estrogen receptor-β (ER-β) expression, with no significant effect of androgen receptor (AR) and 5α-reductase expression. It decreased mRNA expression of IGF-1 and IGF-1R and protein expression ratio of pAkt/total Akt induced by testosterone. Furthermore, it significantly ameliorated testosterone-induced reduction of mRNA expression Bax/Bcl-2 ratio, P21 and phosphatase and tensin homolog (PTEN) and AMPK [PT-172] activity. In conclusion, these findings elucidate the effectiveness of metformin in preventing testosterone-induced BPH in rats. These results could be attributed, at least partly, to its ability to enhance expression ratio of ER-β/ER-α, decrease IGF-1, IGF-1R and pAkt expressions, increase P21, PTEN, Bax/Bcl-2 expressions and activate AMPK with a subsequent inhibition of prostate proliferation.

Citing Articles

The consequences of climate change and male reproductive health: A review of the possible impact and mechanisms.

Akhigbe R, Oyedokun P, Akhigbe T, Hamed M, Fidelis F, Omole A Biochem Biophys Rep. 2024; 41:101889.

PMID: 39717849 PMC: 11664087. DOI: 10.1016/j.bbrep.2024.101889.

Asiatic acid mitigates testosterone-induced benign prostatic hyperplasia in rats via activation of PPAR-γ.

Kamal H, Almutairi B, Abdel-Naim A Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1991-2001.

PMID: 39222244 DOI: 10.1007/s00210-024-03405-z.

Metformin: A promising clinical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation.

Yang T, Yuan J, Peng Y, Pang J, Qiu Z, Chen S J Pharm Anal. 2024; 14(1):52-68.

PMID: 38352949 PMC: 10859540. DOI: 10.1016/j.jpha.2023.08.012.

Effect of C-Type Natriuretic Peptide (CNP) on Spermatozoa Maturation in Adult Rat Epididymis.

Zhao H, Yu Y, Mei C, Zhang T, Kang Y, Li N Curr Issues Mol Biol. 2023; 45(2):1681-1692.

PMID: 36826053 PMC: 9955803. DOI: 10.3390/cimb45020108.

Cordycepin Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats via Modulation of AMPK and AKT Activation.

Alamoudi A, Alessi S, Rizg W, Jali A, Safhi A, Sabei F Pharmaceutics. 2022; 14(8).

PMID: 36015278 PMC: 9415290. DOI: 10.3390/pharmaceutics14081652.

References

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal J . The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008; 8(3):187-98. DOI: 10.2174/156800908784293659. View

Yu S, Wong Y, Wang X, Ling M, Ng C, Chen S . Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene. 2007; 27(23):3313-28. DOI: 10.1038/sj.onc.1210986. View

Culig Z, Hobisch A, Cronauer M, Radmayr C, HITTMAIR A, Zhang J . Regulation of prostatic growth and function by peptide growth factors. Prostate. 1996; 28(6):392-405. DOI: 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C. View

Song R, Chen Y, Zhang Z, Bao Y, Yue W, Wang J . Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. 2009; 118(4-5):219-30. PMC: 2826506. DOI: 10.1016/j.jsbmb.2009.09.018. View

Tosca L, Rame C, Chabrolle C, Tesseraud S, Dupont J . Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. Reproduction. 2009; 139(2):409-18. DOI: 10.1530/REP-09-0351. View

Grahame Hardie D . AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8(10):774-85. DOI: 10.1038/nrm2249. View

Donnell R . Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol. 2010; 21(1):22-6. DOI: 10.1097/mou.0b013e32834100dd. View

Dey P, Barros R, Warner M, Strom A, Gustafsson J . Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS. J Mol Endocrinol. 2013; 51(3):T61-74. DOI: 10.1530/JME-13-0150. View

LYTTON B, Emery J, HARVARD B . The incidence of benign prostatic obstruction. J Urol. 1968; 99(5):639-45. DOI: 10.1016/S0022-5347(17)62763-0. View

10.

Jacobsen S, Girman C, Lieber M . Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16. DOI: 10.1016/s0090-4295(01)01298-5. View

11.

Wadsworth T, Carroll J, Mallinson R, Roberts Jr C, Roselli C . Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology. 2004; 145(7):3205-14. DOI: 10.1210/en.2003-1716. View

12.

Takeda H, Nakamoto T, Kokontis J, Chodak G, Chang C . Autoregulation of androgen receptor expression in rodent prostate: immunohistochemical and in situ hybridization analysis. Biochem Biophys Res Commun. 1991; 177(1):488-96. DOI: 10.1016/0006-291x(91)92010-h. View

13.

Peehl D, Cohen P, Rosenfeld R . The insulin-like growth factor system in the prostate. World J Urol. 1995; 13(5):306-11. DOI: 10.1007/BF00185974. View

14.

Kim S, Choi H . Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun. 2012; 425(4):866-72. DOI: 10.1016/j.bbrc.2012.07.165. View

15.

Goto M, Iwase A, Harata T, Takigawa S, Suzuki K, Manabe S . IGF1-induced AKT phosphorylation and cell proliferation are suppressed with the increase in PTEN during luteinization in human granulosa cells. Reproduction. 2009; 137(5):835-42. DOI: 10.1530/REP-08-0315. View

16.

LeRoith D, Roberts Jr C . The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195(2):127-37. DOI: 10.1016/s0304-3835(03)00159-9. View

17.

Maggi C, Manzini S, Giuliani S, Meli A . Infravesical outflow obstruction in rats: a comparison of two models. Gen Pharmacol. 1989; 20(3):345-9. DOI: 10.1016/0306-3623(89)90271-1. View

18.

Berstein L, Yue W, Wang J, Santen R . Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat. 2010; 128(1):109-17. DOI: 10.1007/s10549-010-1072-z. View

19.

Malki A, Youssef A . Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011; 19(6):275-85. DOI: 10.3727/096504011x13021877989838. View

20.

Febbraro T, Lengyel E, Romero I . Old drug, new trick: repurposing metformin for gynecologic cancers?. Gynecol Oncol. 2014; 135(3):614-21. PMC: 4268303. DOI: 10.1016/j.ygyno.2014.10.011. View